Abstract：
With the advent of immune checkpoint inhibitors (ICI), cancer treatment options have widened in recent years. However, ICI-specific adverse events (irAEs) have been reported. Lower gastrointestinal lesions, such as colitis and enteritis, account for most gastrointestinal irAEs, and reports of upper gastrointestinal lesions are rare. We report a rare case of gastroesophagitis associated with ICI. The patient was a 64-year-old male. He was diagnosed with lung adenocarcinoma stage IIIB (cT2aN3M0), and pembrolizumab (PEM) was started as a first-line treatment. Severe gastroesophagitis with laryngopharyngitis was confirmed 5 months after PEM administration. These improved after withdrawal of PEM and steroid administration. Reports of ICI-associated gastritis remain limited, especially with laryngopharyngitis;therefore, we consider this case as valuable, in which we confirmed the clinical features of ICI-associated gastroesophagitis and its therapeutic effects.
摘要：
随着免疫检查点抑制剂（ICI）的出现，近年来，癌症治疗选择已经扩大。然而,已经报道了ICI特异性不良事件(irAE)。下消化道病变,比如结肠炎和肠炎，占大多数胃肠道感染的比例，上消化道病变的报告很少见。我们报告了与ICI相关的罕见胃食管炎病例。患者为64岁男性。他被诊断为肺腺癌IIIB期（cT2aN3M0），派姆单抗(PEM)开始作为一线治疗.PEM给药5个月后证实了严重的胃食管炎伴咽喉炎。这些在PEM和类固醇给药后改善。ICI相关性胃炎的报告仍然有限，尤其是喉咽炎；因此，我们认为这个案子很有价值，其中我们证实了ICI相关性胃食管炎的临床特征及其治疗效果。
